Hypoxia as a target for combined modality treatments

European Journal of Cancer

Volumn 38, Issue 2, 2002, Pages 240-257

  Wouters, B G ^a   Weppler, S A ^a   Koritzinsky, M ^a   Landuyt, W ^a   Nuyts, S ^a   Theys, J ^a   Chiu, R K ^a   Lambin, P ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Gene expression; Radiation resistance; Translational research; Tumour hypoxia

Indexed keywords

CARBOGEN; ERYTHROPOIETIN; NICOTINAMIDE; RADIOSENSITIZING AGENT;

ANGIOGENESIS; APOPTOSIS; ARTICLE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC STABILITY; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; HYPOXIC CELL; METASTASIS; MICROENVIRONMENT; MULTIMODALITY CANCER THERAPY; PH; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TISSUE OXYGENATION; TUMOR VASCULARIZATION; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBON DIOXIDE; CELL HYPOXIA; COMBINED MODALITY THERAPY; GENE EXPRESSION; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; OXYGEN; PROGNOSIS; RADIATION-SENSITIZING AGENTS;

EID: 0036173591     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00361-6     Document Type: Article

References (253)

1. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix
2. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
3. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
4. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
5. Intratumoral oxygen tension in metastatic melanoma
6. Radiobiological and immunohistochemical assessment of hypoxia in human melanoma xenografts: Acute and chronic hypoxia in individual tumours
7. Oxygenation of human tumors: Evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements
8. Oxygenation of mammary tumors as evaluated by ultrasound-guided computerized-pO2-histography
9. Hypoxic regions exist in human prostate carcinoma
10. Invasive oxygen measurements and pimonidazole labeling in human cervix carcinoma
11. A comparison in individual murine tumors of techniques for measuring oxygen levels
12. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts
13. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome
14. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma
15. Oxygenation predicts radiation response and survival in patients with cervix cancer
16. Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations
17. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy
18. The effect of hypoxia on the growth and radiation response of mammalian cells in culture
19. The influence of microenvironmental factors during cancer therapy
20. Role of tumor vascular architecture in nutrient and drug delivery: An invasion percolation-based network model
21. Hypoxia induces DNA overreplication and enhances metastatic potential of murine tumor cells
22. Relationship of hypoxia to metastatic ability in rodent tumours
23. Hypoxia-induced tumour cell migration in an in vivo chicken model
24. Matrix metalloproteinases: Molecular aspects of their roles in tumour invasion and metastasis
25. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer
26. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer
27. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma
28. Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells
29. Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit
30. Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression
31. Both increased stability and transcription contribute to the induction of the urokinase plasminogen activator receptor (uPAR) message by hypoxia
32. Urokinase induces receptor mediated brain tumor cell migration and invasion
33. Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability
34. Hypoxia-induced elevation in interleukin-8 expression by human ovarian carcinoma cells
35. Cooperation between transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia
36. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma. A potential mechanism for high tumor aggressiveness
37. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer
38. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis
39. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
40. Estimating the selective advantage of mutant p53 tumour cells to repeated rounds of hypoxia
41. Selection of human cervical epithelial cells that possess reduced apoptotic potential to low-oxygen conditions
42. Response of tumour cells to hypoxia: Role of p53 and NFkB
43. Loss of PTEN facilitates HIF-1-mediated gene expression
44. Hypoxic cervical cancers with low apoptotic index are highly aggressive
45. Regulation of hypoxia-induced angiogenesis: A chaperone escorts VEGF to the dance
46. Hypoxia-induced metastasis of human melanoma cells: Involvement of vascular endothelial growth factor-mediated angiogenesis
47. Regulation of angiogenesis via vascular endothelial growth factor receptors
48. An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release
49. Induction of the angiogenic modulator fibroblast growth factor-binding protein by epidermal growth factor is mediated through both MEK/ERK and p38 signal transduction pathways
50. Selective activation of p38alpha and p38gamma by hypoxia. Role in regulation of cyclin D1 by hypoxia in PC12 cells
51. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells
52. Hypoxia induces differential expression of the integrin receptors alpha(vbeta3) and alpha(vbeta5) in cultured human endothelial cells
53. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3
54. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2
55. Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: Relationships to pretreatment tumor oxygenation and vascularization
56. The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas
57. Tissue oxygen distribution in head and neck cancer patients
58. Oxygenation of squamous cell carcinoma of the head and neck: Comparison of primary tumors, neck node metastases, and normal tissue
59. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy
60. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer
61. Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer
62. Correlation of high lactate levels in human cervical cancer with incidence of metastasis
63. Correlation of high lactate levels in head and neck tumors with incidence of metastasis
64. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review
65. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer
66. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix
67. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis
68. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
69. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells
70. The regulated expression of erythropoietin by two human hepatoma cell lines
71. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension
72. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms
73. Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: Similarities with the erythropoietin 3′ enhancer
74. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1
75. Pretranslational regulation of two cardiac glucose transporters in rats exposed to hypobaric hypoxia
76. Isoenzyme-specific regulation of genes involved in energy metabolism by hypoxia: Similarities with the regulation of erythropoietin
77. Regulation of c-jun expression during hypoxic and low-glucose stress
78. Rabbit aortic endothelial cell hypoxia induces secretion of transforming growth factor beta and augments macrophage adhesion in vitro
79. Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents
80. Hypoxia stimulates urokinase receptor expression through a heme protein- dependent pathway
81. Hypoxia increases rate of transcription and stability of tyrosine hydroxylase mRNA in pheochromocytoma (PC12) cells
82. Hypoxia-induced pRB hypophosphorylation results from downregulation of CDK and upregulation of PP1 activities
83. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
84. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
85. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR
86. Expression of the oxygen-regulated protein ORP150 accelerates wound healing by modulating intracellular VEGF transport
87. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: Implications for translation under hypoxia
88. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription
89. The vascular endothelial growth factor mRNA contains an internal ribosome entry site
90. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation
91. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status
92. Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia
93. Nuclear factor interleukin 6 motifs mediate tissue-specific gene transcription in hypoxia
94. Hypoxia-associated induction of early growth response-1 gene expression
95. Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues
96. Hypoxia-inducible factor 1: Control of oxygen homeostasis in health and disease
97. A 24-base-pair sequence 3′ to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer
98. Hypoxia regulatory elements of the human vascular endothelial growth factor gene
99. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter
100. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia
101. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha
102. Characterization of hypoxia-responsive enhancer in the human erythropoietin gene shows presence of hypoxia-inducible 120-Kd nuclear DNA-binding protein in erythropoietin-producing and nonproducing cells
103. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia
104. Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein
105. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes
106. In vivo expression of mRNAs encoding hypoxia-inducible factor 1
107. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
108. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway
109. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway
110. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation
111. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing
112. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers
113. Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide
114. Sensitization of hypoxic tumour cells - Clinical experience
115. Prognostic value of pretreatment factors in patients with locally advanced carcinoma of the uterine cervix treated by radiotherapy alone
116. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: Results of a retrospective study of 386 patients
117. Prognostic factors for local and distant recurrence in stage I and II cervical carcinoma
118. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx
119. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27
120. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma
121. T1/T2 glottic cancer managed by external beam radiotherapy: The influence of pretreatment hemoglobin on local control
122. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study
123. Radiation myelitis and survival in the radiotherapy of lung cancer
124. Results of treatment and lessons learned from pathologically staged T4 non-small cell lung cancer
125. The effect of arterial oxygen content on the results of radiation therapy for epidermoid bronchogenic carcinoma
126. Local control of muscle-invasive bladder cancer: Preoperative radiotherapy and cystectomy versus cystectomy alone
127. Blood tests and prognosis in bladder carcinomas treated with definitive radiotherapy
128. DNA analysis in predicting survival of irradiated patients with transitional cell carcinoma of bladder
129. Prognostic factors in patients with bladder carcinoma treated with definitive irradiation
130. The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate
131. The significance of anemia in clinical radiation therapy
132. Clinical trial experience using erythropoietin during radiation therapy
133. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer
134. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx
135. Extrapolations from laboratory and preclinical studies for the use of carbogen and nicotinamide in radiotherapy
136. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor
137. Radiosensitization with normobaric oxygen and carbogen
138. Changes in the oxygenation of head and neck tumors during carbogen breathing
139. Reducing acute and chronic hypoxia in tumours by combining nicotinamide with carbogen breathing
140. Carbogen breathing with nicotinamide improves the oxygen status of tumours in patients
141. The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing
142. The effects of carbogen and nicotinamide on intravascular oxyhaemoglobin saturations in SCCVII and KHT murine tumours
143. Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy
144. ARCON - Current status: Summary of a workshop on preclinical and clinical studies
145. Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single- and multifraction irradiation
146. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer
147. Clinical outcome and tumour microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide
148. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide
149. ARCON: Accelerated radiotherapy with carbogen and nicotinamide in head and neck squamous cell carcinomas. The experience of the Co-operative group of radiotherapy of the European Organization for Research and Treatment of Cancer (EORTC)
150. ARCON: Accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: A phase I/II study by the EORTC
151. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: Report of European Organization for Research and Treatment of Cancer trial 22933
152. Studies of the pharmacokinetic properties of nimorazole
153. A phase I clinical study of Nimorazole as a hypoxic radiosensitizer
154. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
155. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors
156. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer
157. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer
158. Tirapazamine: A new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer
159. SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours
160. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin
161. Potentiation of cisplatin activity by the bioreductive agent tirapazamine
162. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: A phase II study
163. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer
164. An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin
165. AQ4N: A new approach to hypoxia-activated cancer chemotherapy
166. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent
167. AQ4N: An alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo
168. Chemotherapeutic tumour targeting using clostridial spores
169. Colonisation of Clostridium in the body is restricted to hypoxic and necrotic areas of tumours
170. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo
171. Tumor-targeted Salmonella as a novel anticancer vector
172. Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas
173. Stable Escherichia coli-Clostridium acetobutylicum shuttle vector for secretion of murine tumor necrosis factor alpha
174. Anaerobic bacteria as a delivery system for cancer gene therapy: In vitro activation of 5-fluorocytosine by genetically engineered clostridia
175. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment
176. Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum
177. The use of radiation-induced bacterial promoters in anaerobic conditions: A means to control gene expression in clostridium-mediated therapy for cancer
178. Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors
179. Evidence for characteristic vascular patterns in solid tumours: Quantitative studies using corrosion casts
180. Microvascular corrosion casting in the study of tumor vascularity: A review
181. Vascular attack as a therapeutic strategy for cancer
182. Endothelial-cell proliferation in experimental tumours
183. Tumor angiogenesis: Therapeutic implications
184. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
185. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
186. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
187. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2- carboxamidines: An important new class of selective synthetic urokinase inhibitor
188. The power of the front page of The New York Times
189. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
190. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
191. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
192. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth
193. Thalidomide is an inhibitor of angiogenesis
194. The effect of thalidomide on experimental tumors and metastases
195. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
196. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
197. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
198. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
199. Nuclease-resistant synthetic ribozymes: Developing a new class of therapeutics
200. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo
201. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
202. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
203. Definition of two angiogenic pathways by distinct alpha v integrins
204. Requirement of vascular integrin alpha v beta 3 for angiogenesis
205. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
206. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin
207. Alpha v integrins as receptors for tumor targeting by circulating ligands
208. Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3- specific humanized mAb
209. Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3
210. Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI
211. Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12
212. Inhibition of angiogenesis in vivo by interleukin 12
213. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis
214. Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients
215. Phase I study of the antineovascularization drug CM101
216. Vascular endothelium as the vulnerable element in tumours
217. Cells at intermediate oxygen levels can be more important than the "hypoxic fraction" in determining tumor response to fractionated radiotherapy
218. Vinca alkaloids: Anti-vascular effects in a murine tumour
219. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors
220. The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels
221. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown
222. Flavone acetic acid directly induces expression of cytokine genes in mouse splenic leukocytes but not in human peripheral blood leukocytes
223. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: A novel approach to cancer therapy
224. Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488)
225. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism
226. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a)
227. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4
228. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs
229. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature
230. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: Effects on radiation therapy
231. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues
232. Vascular targeting of solid tumours: A major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas
233. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo
234. Transcription factor hif-1 is a necessary mediator of the pasteur effect in mammalian cells
235. Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy
236. Suppression of tumor growth through disruption of hypoxia-inducible transcription
237. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
238. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-kappaB inhibition
239. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB
240. Proteasome inhibition: A new strategy in cancer treatment
241. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth
242. Hypoxia modulated gene expression: Angiogenesis, metastasis and therapeutic exploitation
243. Targeting gene expression to hypoxic tumor cells
244. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes
245. Development of a hypoxia-responsive vector for tumor-specific gene therapy
246. Effect of local hyperthermia on blood flow and microenvironment: A review
247. Tumour microcirculation as a target for hyperthermia
248. Hyperthermic treatment of malignant diseases: Current status and a view toward the future
249. Photodynamic therapy
250. Photodynamic therapy in oncology: Mechanisms and clinical use
251. Toxic effect of tumor necrosis factor on tumor vasculature in mice
252. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
253. Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents